Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Multi-kinase Inhibitors + Bevacizumab in High-Risk HCC Post-Transplant
NCT06041490Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, sorafenib, lenvatinib, donafenib in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
bevacizumabsorafeniblenvatinibdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06041490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041490.